The Swiss stock market recently extended its ongoing record streak, with the Swiss Market Index surpassing 15,000 points for the first time in history. This milestone followed double-digit percentage gains in October, though index heavyweights Roche and Novartis paused to absorb their previous advances. Following a pullback on the New York market, the Swiss benchmark encountered downward pressure.
Strategists at Deutsche Bank found themselves in an awkward position after upgrading the technology sector from neutral to overweight on a Thursday afternoon, specifically promoting hardware manufacturer equities just as prices in New York began to slide. Market observers noted that this segment has endured a painful valuation correction in recent weeks, leaving open the possibility that prices could soon reach a floor. Meanwhile, recent trading drew demand toward prior year-to-date laggards in the Swiss Market Index, including Partners Group, Amrize, and Holcim, aided by strong results from Democrats in midterm elections that market participants suggest will complicate abrupt shifts in economic policy.
Lonza featured among the weekly winners following an investor day in Vacaville, California, which preceded the announcement that the pharmaceutical supplier is acquiring five production facilities from Germany's Merck. While the official media release cited a low to mid-three-digit million amount, statements from Chief Executive Officer Wolfgang Wienand during an analyst conference pointed toward a purchase price between 350 million and 400 million Swiss francs. Analysts noted the transaction appears favorable given that the five plants may currently operate below full capacity, leaving room for profitability gains. The financial outlay reportedly leaves Lonza's planned 500 million franc share buyback program intact, though observers described the equity as potentially overheated following recent gains.
In corporate control developments, building technology company Meier Tobler received a cash takeover offer from Sweden's Ahlsell valued at roughly 490 million francs, or 45.50 francs per share. This represents a premium of over 30 percent compared to the volume-weighted average price of the preceding 60 trading days. The target's board of directors and family shareholders, including Silvan Meier with roughly 57 percent of the voting rights, have backed the transaction, having tendered their stake for nearly 294 million francs. Zürcher Kantonalbank characterized the offer as attractive and strategically sound while maintaining a market-weight rating.
At PolyPeptide, filings with SIX Swiss Exchange showed that Samsung Biologics received remaining shares and synthetic participation rights ahead of a deadline, encompassing transactions totaling nearly 22 million francs. The development concludes a public chapter that began with an April 2021 initial public offering at 64 francs per share, leaving long-term holders with losses following earlier trading peaks above 140 francs. A squeeze-out and subsequent delisting are now anticipated.
At Rieter, designated Chief Executive Officer Daniel Lippuner parted ways with the firm before taking office after requesting additional compensation terms. The Winterthur-based textile machinery manufacturer appointed former Barmag head Georg Stausberg as his successor. Stausberg faces tasks that include integrating Barmag while Rieter shares trade near long-term lows.
Additionally, orthopedics firm Medacta issued an earnings and revenue warning, revising its projected operating margin for the year to approximately 27.9 percent from 28.4 percent previously, and cutting its anticipated revenue growth rate to roughly 9 percent from a prior range of 10 to 14 percent.
